Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections

NCT05615805
View directory record Official record
Conditions
Intravitreal Injection, Ocular Rinse, Age-Related Macular Degeneration, Diabetic Macular Edema, Cystoid Macular Edema
Interventions
OSDI questionnaire, SPEEDII questionnaire
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 21, 2026, 5:03 PM EDT
Not yet recruiting No phase listed Observational

Vascular Endothelial Inflammation and Health Status In INOCA (VISION-INOCA)

NCT07586241
View directory record Official record
Conditions
Ischemia and Non-obstructive Coronary Arteries
Interventions
Invasive coronary angiography, Coronary Artery Endothelial Cell Sampling, Fitbit, Invasive coronary function testing
Procedure · Device · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing

NCT01193231
View directory record Official record
Conditions
Must be PRK Candidate
Interventions
Not listed
Lead sponsor
Durrie Vision
Other
Eligibility
18 Years to 39 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 21, 2026, 5:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Optimize Pediatric OCT Imaging

NCT06139523
View directory record Official record
Conditions
Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions
Investigational contact OCT system, Investigational noncontact OCT system:
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

NCT03891446
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, Standard of Care
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
66
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Not listed Phase 2 Interventional

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Vision-Guided Shared Control for Assistive Robotics Manipulators

NCT04323449
View directory record Official record
Conditions
Spinal Cord Injury/Disorder
Interventions
Compare two control methods for a wheelchair-mounted robotic manipulator
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Stop Retinal Ganglion Cell Dysfunction Study

NCT02390284
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 21, 2026, 5:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Novel Glaucoma Diagnostics

NCT00286637
View directory record Official record
Conditions
Glaucoma, Macular Disease
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 21, 2026, 5:03 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 21, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT02521311
View directory record Official record
Conditions
Optic Neuritis
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

NCT01200238
View directory record Official record
Conditions
Ocular Melanoma
Interventions
STA-9090
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 21, 2026, 5:03 PM EDT
Not listed Not applicable Interventional

Effect of Peripheral Laser Iridotomy Placement on Post-operative Visual Function

NCT03352492
View directory record Official record
Conditions
Glaucoma, Angle-Closure
Interventions
Superior laser peripheral iridotomy, Temporal laser peripheral iridotomy
Procedure
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 21, 2026, 5:03 PM EDT
Not listed Not applicable Interventional

Effects of Xal-Ease on Patient Compliance With Xalatan

NCT00573638
View directory record Official record
Conditions
Glaucoma
Interventions
Xal-Ease device to be used with Xalatan eye drops
Device
Lead sponsor
Augusta University
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Evaluation of Pascal Laser Trabeculoplaty

NCT00838721
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
laser trabeculoplasty
Other
Lead sponsor
Santa Clara Valley Health & Hospital System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 21, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

Adjuvant Tebentafusp in High Risk Ocular Melanoma

NCT06246149
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Tebentafusp
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992
View directory record Official record
Conditions
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Interventions
Tepotinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
39
States / cities
Duarte, California • Encinitas, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Not applicable Interventional

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

NCT03076671
View directory record Official record
Conditions
Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions
Palliative Care
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 105 Years
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 21, 2026, 5:03 PM EDT
Terminated Not applicable Interventional Results available

Validation of Brain Oxygenation Monitor on Pediatric Patients

NCT00849940
View directory record Official record
Conditions
Cardiac Catheterization
Interventions
CAS NIRS FORE-SIGHT oximeter
Device
Lead sponsor
Duke University
Other
Eligibility
Up to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma

NCT00074191
View directory record Official record
Conditions
Lymphoma
Interventions
cytarabine, dexamethasone, lomustine, methotrexate, procarbazine hydrochloride
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
16 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 21, 2026, 5:03 PM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Sickle Trait

NCT00720317
View directory record Official record
Conditions
Diabetic Retinopathy, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SHAPE:SeeingtheHeartwithAIPoweredEcho

NCT03705650
View directory record Official record
Conditions
Cardiac Disease
Interventions
Limited Echocardiogram
Diagnostic Test
Lead sponsor
Sara Guttas
Industry
Eligibility
65 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winfield, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 21, 2026, 5:03 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

NCT06323174
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Huntington Park, California • Northridge, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 5:03 PM EDT